Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03958955 |
Recruitment Status :
Terminated
(Terminated due to recruitment challenges.)
First Posted : May 22, 2019
Results First Posted : June 28, 2021
Last Update Posted : June 28, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Discoid Lupus Erythematosus | Drug: Delgocitinib cream Drug: Delgocitinib cream vehicle | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This was a phase 2a, within-subject trial design, where all subjects were treated with active treatment on one DLE target lesion and vehicle treatment on another DLE target lesion. |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Twice-daily Application of Delgocitinib Cream 20 mg/g for 6 Weeks in Subjects With Active Discoid Lupus Erythematosus. |
Actual Study Start Date : | July 9, 2019 |
Actual Primary Completion Date : | April 15, 2020 |
Actual Study Completion Date : | April 30, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Delgocitinib cream 20 mg/g
Delgocitinib cream applied twice daily for 6 weeks
|
Drug: Delgocitinib cream
Cream for topical application.
Other Name: LEO 124249 cream |
Placebo Comparator: Delgocitinib cream vehicle
Delgocitinib cream vehicle applied twice daily for 6 weeks
|
Drug: Delgocitinib cream vehicle
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Other Name: LEO 124249 cream vehicle |
- Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6. [ Time Frame: Week 6 ]The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
- Number of Adverse Events (AEs) up to Week 6. [ Time Frame: Week 0 to Week 6 ]Number of AEs from baseline to Week 6
- Number of Subjects With AEs up to Week 6. [ Time Frame: Week 0 to Week 6 ]Number of subjects with AEs from baseline to Week 6
- Number of Lesion-specific, Treatment-related AEs up to Week 6. [ Time Frame: Week 0 to Week 6 ]The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion).
- Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline. [ Time Frame: Week 0 to Week 6 ]The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.
- Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline. [ Time Frame: Week 0 to Week 6 ]The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
- Erythema Score at Week 6. [ Time Frame: Week 6 ]The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.
- Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6. [ Time Frame: Week 6 ]The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Histopathological findings (current or previous) consistent with clinical diagnosis of DLE.
- Unequivocal clinical diagnosis of 2 active DLE target lesions that were <6 months old and amenable for clinical evaluation. This included lesions located on the scalp if they fulfilled all lesion-specific eligibility criteria.
- Target lesion IGA score of at least moderate severity (≥3) at screening and baseline.
- Target lesion erythema score ≥2 at screening and baseline.
Main Exclusion Criteria:
- Target lesion dyspigmentation score of 2 at screening or baseline.
- Target lesion scarring/atrophy score of 2 at screening or baseline.
- Target lesion scarring alopecia score of >0 in scalp lesions at screening or baseline.
- Medical history of systemic lupus erythematosus (SLE) with clinically significant organ involvement (American College of Rheumatology SLE classification criteria no. 6 to 9) including SLE-related pleuritis or pericarditis (by clinical evaluation and electrocardiogram), and neurologic, renal, and/or other major SLE-related organ system involvement. SLE joint involvement was acceptable.
- Subjects with unstable or significant SLE disease activity findings that would, by its progressive nature and/or severity, interfere with the trial evaluation, completion, and/or procedures per the investigator's discretion.
- Other skin conditions at screening or baseline that would interfere with the evaluation of DLE.
- Immunosuppressive/immunomodulating therapy with e.g. methotrexate, cyclosporine, azathioprine, retinoids (both topical and systemic), or dapsone within 4 weeks prior to baseline.
- Systemic prednisolone >7.5 mg/day or changed dose within 4 weeks prior to baseline (nasal and inhaled corticosteroids were allowed).
-
Treatment with the following medications:
- Oral antimalarial treatment with hydroxychloroquine >6.5 mg/kg body weight/day, or chloroquine >4 mg/kg body weight/day, or changed dose within 12 weeks prior to baseline.
- Quinacrine combined with either hydroxychloroquine or chloroquine within 12 weeks prior to baseline.
- Drugs known to interact with antimalarials (e.g. digoxin, cimetidine) within 12 weeks prior to baseline.
- Treatment with topical corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors within 2 weeks prior to baseline.
- Use of systemic antibiotics or cutaneously applied antibiotics on the target lesions within 2 weeks prior to baseline.
- Ultraviolet (UV) therapy within 2 weeks prior to baseline.
- Any procedure impairing the skin barrier (e.g. incision) within 2 cm from the border of any of the target lesions within 4 weeks prior to baseline.
- Receipt of live (attenuated) vaccines within 4 weeks prior to baseline.
-
Treatment with any marketed biological therapy or investigational biologic agents:
- Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returned to normal, whichever was longer.
- Other biologics: within 3 months or 5 half-lives, whichever was longer, prior to baseline.
- Unstable or fluctuating use of tobacco within 1 month prior to screening which, in the opinion of the investigator, could affect the natural course of the disease and thus affect the evaluation of the treatment.
- History of any active skin infection within 1 week prior to baseline.
-
Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, could compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial. Clinically significant infections are defined as:
- A systemic infection.
- A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
- Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive blood test for tuberculosis at screening. Subjects with high risk of latent tuberculosis (e.g. prior residence in or travel to countries with high prevalence of tuberculosis, close contact with a person with active tuberculosis, or a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed) must have been tested at screening.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03958955
United States, California | |
LEO Pharma Investigational Site | |
San Diego, California, United States, 92103 | |
United States, Illinois | |
LEO Pharma Investigational Site | |
Skokie, Illinois, United States, 60077 | |
United States, Massachusetts | |
LEO Pharma Investigational Site | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
LEO Pharma Investigational Site | |
Forest Hills, New York, United States, 11375 | |
United States, Ohio | |
LEO Pharma Investigational Site | |
Cincinnati, Ohio, United States, 45219 | |
Denmark | |
LEO Pharma Investigational Site | |
Aarhus, Denmark, 8200 | |
LEO Pharma Investigational site | |
Hellerup, Denmark, 2900 | |
LEO Pharma Investigational Site | |
Odense, Denmark, 5000 | |
France | |
LEO Pharma Investigational Site | |
Loiré, France, 42000 | |
LEO Pharma Investigational Site | |
Nice, France, 06202 | |
LEO Pharma Investigational Site | |
Paris, France, 75010 | |
LEO Pharma Investigational Site | |
Toulouse, France, 31000 | |
Germany | |
LEO Pharma Investigational Site | |
Aachen, Germany, 52074 | |
LEO Pharma Investigational Site | |
Berlin, Germany, 10117 | |
LEO Pharma Investigational Site | |
Bochum, Germany, 44791 | |
LEO Pharma Investigational Site | |
Dresden, Germany, 01307 | |
LEO Pharma Investigational Site | |
Duesseldorf, Germany, 40225 | |
LEO Pharma Investigational Site | |
Erlangen, Germany, 91054 | |
LEO Pharma Investigational Site | |
Oldenburg, Germany, 26133 |
Study Director: | Medical Expert | LEO Pharma |
Documents provided by LEO Pharma:
Responsible Party: | LEO Pharma |
ClinicalTrials.gov Identifier: | NCT03958955 |
Other Study ID Numbers: |
EXP-1373 2018-003615-22 ( EudraCT Number ) |
First Posted: | May 22, 2019 Key Record Dates |
Results First Posted: | June 28, 2021 |
Last Update Posted: | June 28, 2021 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | De-identified individual patient data (IPD) can be made available to researchers in a closed environment for a specified period of time. Data sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
Time Frame: | Data is available to request after approval of the studied indication. |
URL: | https://www.leopharmatrials.com/en/for-professionals |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lupus Erythematosus, Systemic Lupus Erythematosus, Discoid Connective Tissue Diseases Autoimmune Diseases |
Immune System Diseases Lupus Erythematosus, Cutaneous Skin Diseases |